Zura Bio Ltd (ZURA) SEC Filings, Mar-Apr 2026

Zura Bio Ltd reported that Chief Executive Officer Sandeep Chidambar Kulkarni received an award of employee share options covering 894,000 Class A Ordinary Shares. The options have an exercise price of 6.03 per share and expire on April 1, 2036.

According to the vesting terms, one fourth of the options will vest on April 1, 2027, and the remaining three fourths will vest in equal quarterly installments thereafter, contingent on his continuous service. Following this grant, he holds 894,000 options directly.

Zura Bio Limited is a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases. It highlights three in-licensed antibody programs: tibulizumab (ZB-106), crebankitug (ZB-168) and torudokimab (ZB-880), all sourced from large pharma partners.

Tibulizumab, a bispecific antibody targeting IL-17A and BAFF, is in two global Phase 2 trials: TibuSHIELD in hidradenitis suppurativa, with topline 16-week data planned for the fourth quarter of 2026, and TibuSURE in diffuse cutaneous systemic sclerosis, with topline 24-week data expected in the first half of 2027.

The filing describes earlier Phase 1 safety and pharmacodynamic data for all three assets, fully outsourced cGMP manufacturing, and composition-of-matter patents generally extending into 2031–2037. It also details substantial milestone and royalty obligations under licenses with Lilly and Pfizer, a Lonza gene-expression license, WuXi Biologics agreements, and a 2025 Athanor letter agreement that included issuing 8,657,402 shares plus cash and future sales-based obligations.

Zura Bio Limited reported full-year 2025 results and highlighted progress across its clinical pipeline and financing. The company posted a net loss of $68.7 million for 2025, compared with $52.4 million in 2024, as research and development spending increased to $42.1 million to advance Phase 2 tibulizumab trials.

Cash and cash equivalents were $109.4 million as of December 31, 2025, down from $176.5 million a year earlier. In February 2026, Zura completed an underwritten equity offering with gross proceeds of about $144 million, and now believes its cash can fund operations through at least the end of 2028.

The Phase 2 TibuSHIELD study in hidradenitis suppurativa expanded planned enrollment to 225 participants, with topline data expected in the fourth quarter of 2026. The TibuSURE Phase 2 study in systemic sclerosis is ongoing, with topline data anticipated in the first half of 2027. Leadership updates include appointing Sandeep Kulkarni, M.D., as Chief Executive Officer in January 2026 and adding two new board members in February 2026.

Zura Bio Limited furnished a new corporate presentation for investors and conferences dated March 10, 2026. The materials are provided under a Regulation FD disclosure to share updated information with the market.

The presentation is available as Exhibit 99.1 and can also be accessed through the company’s investor relations website in the “News & Events” section. The materials are furnished, not filed, and are not automatically incorporated into other SEC filings.

Nirula Ajay reported acquisition or exercise transactions in this Form 4 filing.

Zura Bio Ltd director Ajay Nirula reported receiving a grant of 37,812 share options. These options were awarded on February 21, 2026 and vest in twelve substantially equal monthly installments over one year starting from that date. Any remaining unvested options will vest on the day immediately before the next annual meeting of shareholders following the grant date, as long as he continues in service through each vesting date.

Zura Bio Ltd director Ajay Nirula filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director and does not report any insider purchase, sale, acquisition, or disposition transactions in the summarized data.

Zura Bio Limited filed a current report describing a press release about its Phase 2 TibuSURE study of tibulizumab (ZB-106) in diffuse cutaneous systemic sclerosis. The company will present the study design as a poster at the 9th Systemic Sclerosis World Congress in Athens.

The global, randomized, double-blind, placebo-controlled Phase 2 trial is expected to enroll about 80 adults, treated every four weeks for 24 weeks, followed by a 28‑week open-label extension. The primary endpoint is change in modified Rodnan Skin Score at Week 24, with topline results anticipated in the first half of 2027.

Tibulizumab is an investigational dual-pathway antibody targeting IL-17A and BAFF. Zura highlights that no clinical efficacy or safety data will be presented in the poster; it focuses on study rationale and design only.

Zura Bio Ltd reported that affiliated entity AI Biotechnology LLC, a 10% owner, bought 2,000,000 Class A Ordinary Shares of Zura Bio.

The shares were acquired at $6.25 per share in a registered offering by the company, increasing AI Biotechnology LLC’s direct holdings to 6,552,725 shares. Related entities, including Access Industries Holdings LLC, Access Industries Management, LLC and Len Blavatnik, may be deemed beneficial owners through their control structure but each disclaims beneficial ownership beyond any pecuniary interest.

Zura Bio Limited’s major shareholder group updated its ownership disclosure in this Schedule 13D amendment. AI Biotechnology LLC bought 2,000,000 Class A Ordinary Shares on February 26, 2026 at $6.25 per share in a registered offering, funded with capital from affiliated entities.

After this purchase, AI Biotechnology LLC, together with related Access Industries entities and Len Blavatnik, reports beneficial ownership of 19,699,071 Class A Ordinary Shares, or 18.2% of the class. This figure includes 6,552,725 shares held directly and 13,146,346 shares issuable upon exercise of Private Placement Warrants, which are subject to a “Beneficial Ownership Blocker” that generally limits exercises above 9.99%, or up to 19.99% after notice.